The aim of the study is to assess safety, tolerability and clinical effects of differentdoses of riociguat in patients with inoperable Chronic Thromboembolic PulmonaryHypertension (CTEPH) and who are not satisfactorily treated and cannot participate in anyother CTEPH trial. In the US the study runs as an Expanded Access program under 21 CFR312.320.
Not Provided
Drug: Adempas (Riociguat, BAY63-2521)
Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on
patient's well being and blood pressure. (The individual optimal dose should be
determined during the initial 8-week titration phase based on patient's monitoring of
systolic blood pressure and well-being.)
Inclusion Criteria:
- Male and female patients with CTEPH either inoperable or with persistent or
recurrent PH after surgery
Exclusion Criteria:
- All types of pulmonary hypertension other than Dana Point Classification Group 4
- Operable patients listed for PEA (Pulmonary Endarterectomy)
Tucson, Arizona, United States
La Jolla, California, United States
Los Angeles, California, United States
Sacramento, California, United States
Aurora, Colorado, United States
Weston, Florida, United States
Chicago, Illinois, United States
Iowa City, Iowa, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Boston, Massachusetts, United States
Ann Arbor, Michigan, United States
Omaha, Nebraska, United States
Newark, New Jersey, United States
New York, New York, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Fairfield, Ohio, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Providence, Rhode Island, United States
Dallas, Texas, United States
El Paso, Texas, United States
Houston, Texas, United States
Graz, Steiermark, Austria
Innsbruck, Tirol, Austria
Wien, Austria
Bruxelles - Brussel, Belgium
Leuven, Belgium
Calgary, Alberta, Canada
London, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Bogotá, Cundinamarca, Colombia
Bogotá, Distrito Capital de Bogotá, Colombia
Cali, Valle del Cauca, Colombia
Bogotá, Colombia
Santa Fe de Bogotá, Colombia
Praha 2, Czech Republic
Aarhus N, Denmark
Besancon, France
Brest, France
Bron, France
Caen, France
Le Kremlin-bicetre, France
Montpellier, France
Pessac, France
Rouen, France
Vandoeuvre Les Nancy, France
Heidelberg, Baden-Württemberg, Germany
München, Bayern, Germany
Regensburg, Bayern, Germany
Würzburg, Bayern, Germany
Gießen, Hessen, Germany
Greifswald, Mecklenburg-Vorpommern, Germany
Hannover, Niedersachsen, Germany
Köln, Nordrhein-Westfalen, Germany
Homburg, Saarland, Germany
Dresden, Sachsen, Germany
Leipzig, Sachsen, Germany
Hamburg, Germany
Pavia, Italy
Roma, Italy
Trieste, Italy
Nagoya, Aichi, Japan
Sendai, Miyagi, Japan
Bunkyo-ku, Tokyo, Japan
Chiba, Japan
Mexico. D.F., Distrito Federal, Mexico
México D.F., Distrito Federal, Mexico
Monterrey, Nuevo Leon, Mexico
Amsterdam, Netherlands
Nieuwegein, Netherlands
Rotterdam, Netherlands
Almada, Portugal
Coimbra, Portugal
Lisboa, Portugal
Lisboa, Portugal
Novosibirsk, Russian Federation
St. Petersburg, Russian Federation
Barcelona, Spain
Barcelona, Spain
Madrid, Spain
Sevilla, Spain
Linköping, Sweden
Lund, Sweden
Umeå, Sweden
St. Gallen, Sankt Gallen, Switzerland
Lausanne, Vaud, Switzerland
Bern, Switzerland
Zürich, Switzerland
Ankara, Turkey
Istanbul, Turkey
Istanbul, Turkey
Istanbul, Turkey
Izmir, Turkey
Izmir, Turkey
Cambridge, Cambridgeshire, United Kingdom
Sheffield, South Yorkshire, United Kingdom
Newcastle Upon Tyne, Tyne and Wear, United Kingdom
Glasgow, West Dunbartonshire, United Kingdom
Bayer Study Director, Study Director
Bayer